Furthermore, all vaccine strategies currently in development against malaria elicit CD8+ T cells recognizing a limited set of immunodominant, “canonical” MHC-I restricted epitopes within a given antigen resulting in rather focused immune responses that might limit their efficacy [21]. The gene discussed is CD8A; the disease is malaria.